Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alprazolam inhalation - Engage Therapeutics

Drug Profile

Alprazolam inhalation - Engage Therapeutics

Alternative Names: AZ-002; Staccato® alprazolam; STAP-001

Latest Information Update: 25 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alexza Pharmaceuticals
  • Developer Alexza Pharmaceuticals; Engage Therapeutics
  • Class Anxiolytics; Azoles; Benzodiazepines; Hypnosedatives; Small molecules
  • Mechanism of Action GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Epilepsy
  • Discontinued Panic disorder

Most Recent Events

  • 01 Jul 2019 Phase-II clinical trials in Epilepsy in Jamaica, Canada, Australia (Inhalation) prior to July 2019
  • 04 May 2019 Efficacy and adverse events data from a phase IIb trial in Epilepsy presented at the 71th Annual Meeting of the American Academy of Neurology (AAN-2019)
  • 01 Aug 2018 EngageTherapeutics in collaboration with Clinilabs completes a phase I trial for Healthy volunteers in USA (NCT03516305)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top